Evaluating the Use of Dalbavancin for Off-Label Indications.
Taylor K, Williamson J, Luther V, Stone T, Johnson J, Gruss Z, Russ-Friedman C, Ohl C, Beardsley J.
Taylor K, et al. Among authors: ohl c.
Infect Dis Rep. 2022 Apr 11;14(2):266-272. doi: 10.3390/idr14020032.
Infect Dis Rep. 2022.
PMID: 35447884
Free PMC article.